zhang ying

Dr. zhang ying


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ZYzhang ying
zhang ying
HDHouyu Duan
Houyu Duan
GXGaoran Xu
Gaoran Xu
JYJunyuan Yang
Junyuan Yang
Immune checkpoint inhibitor-associated myocarditis (ICI-AM) is rare but potentially fatal. We retrospectively reviewed pre-existing clinical records of 42 patients diagnosed with ICI-AM at Renmin Hospital of Wuhan University between October 2023 and March 2025 and classified them as mild (grade 1–2, n = 29) or severe (grade 3–4, n = 13). Baseline characteristics, electrocardiographic findings, biomarkers, treatment patterns, and clinical outcomes were summarized descriptively. Follow-up information was retrospectively obtained from available clinical records, with an administrative follow-up end date of 31 January 2026. Severe ICI-AM was characterized by more frequent dyspnea, concomitant myasthenia gravis, electrocardiographic abnormalities, and higher troponin, CK-MB, and myoglobin levels, together with more frequent corticosteroid, intravenous immunoglobulin, and additional immunosuppressive treatment. Concomitant myositis was also more frequently observed in severe cases. During follow-up, 13 patients (31.0%) died, including 6 of 13 (46.2%) patients with severe ICI-AM and 7 of 29 (24.1%) with mild ICI-AM. Severe ICI-AM showed a more clinically overt phenotype, frequent neuromuscular involvement, and substantial all-cause mortality. These descriptive findings highlight the clinical heterogeneity of ICI-AM and require further investigation in larger prospective multicenter studies.